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Abstract
A German working group of leading breast cancer experts 
have discussed the votes at the International St. Gallen 
Consensus Conference in Vienna for the treatment of pri-
mary breast cancer with regard to the German AGO (Ar-
beitsgemeinschaft Gynäkologische Onkologie) recom-
mendations for clinical practice in Germany. Three of the 
German breast cancer experts were also members of this 
year’s St. Gallen panel. Comparing the St. Gallen recom-
D. Lüftner, S.Y. Brucker, P.A. Fasching, N. Harbeck, J. Huober, C. 
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mendations with the annually updated treatment recom-
mendations of the Gynecological Oncology Working Group 
(AGO Mamma 2019) and the German S3 Guideline is useful, 
because the recommendations of the St. Gallen panel are 
based on expert opinions of different countries and disci-
plines. The focus of this article is on systemic therapy. The 
motto of this year’s 16th St. Gallen Consensus Conference 
was “Estimating the magnitude of clinical benefit.” The ra-
tionale behind this motto is that, for every treatment deci-
sion, a benefit-risk assessment must be taken into consid-
eration for each patient.
© 2019 S. Karger AG, Basel
Introduction
The objective of the St. Gallen Consensus Conference 
on “Primary Treatment of Early Breast Cancer” in Vienna 
was to establish an international consensus on the treat-
ment of patients with early – nonmetastatic – breast can-
cer in daily clinical practice. The consensus is based on 
the voting outcomes of the St. Gallen panel on current 
clinical questions. This year’s panel consisted of more 
than 50 breast cancer experts from 23 countries, includ-
ing 5 German experts (Table 1). The panelists not only 
represent different countries with different healthcare 
systems and resources, but as a result of the interdisci-
plinary nature of treatment, they also represent different 
areas of expertise. 
Against this background, for several years, a German 
working group has been reviewing the voting results of 
the St. Gallen panelists on the basis of the German guide-
lines [1, 2] and, specifically, the annually updated treat-
ment recommendations of the Gynecological Oncology 
Working Group, section “Mamma” (AGO [Arbeitsge-
meinschaft Gynäkologische Onkologie] Mamma) [1]. 
Thematic Focus of the St. Gallen Consensus
This year’s 16th St. Gallen Consensus Conference had 
the motto “Estimating the magnitude of clinical benefit 
of local and systemic therapies in patients with early 
breast cancer.” The aim was to match the treatment de-
cision to the individual situation of patients with early 
breast cancer. Against the background of evidence-
based data, a benefit-risk assessment is necessary to de-
cide under which conditions treatment is appropriate 
and when not (or no longer) in every individual patient.
The voting questions included local and locoregional 
as well as the systemic treatment of early breast cancer. 
This article focuses on systemic therapy. Relating to ques-
tions concerning surgery and radiotherapy, we would like 
to refer to a different publication [3]. We also refer to the 
initial report in Breast Care focusing on this year’s St. Gal-
len Consensus Conference in Vienna [4].
Significance of Tumor-Infiltrating Lymphocytes and 
Programmed Cell Death Ligand 1 Status
In the context of systemic treatment, pathology is be-
coming increasingly important for treatment decision. 
Further predictive factors are discussed in addition to 
hormone receptor (HR) and HER2 status, such as the role 
of tumor-infiltrating lymphocytes (TILs) or the pro-
grammed cell death ligand 1 (PD-L1) status. 
For early triple-negative breast cancer (TNBC), the 
majority of the St. Gallen panelists voted in favor of rou-
tinely assessing TILs. German experts do not agree with 
this, because there are currently no therapeutic conse-
quences from measuring TILs. In the opinion of the Ger-
man experts, a high TIL percentage does not imply that 
chemotherapy can be omitted. 
The first PD-L1 inhibitor (atezolizumab) has already 
been approved in the US and in Europe in combination 
with nab-paclitaxel for the treatment of patients with met-
astatic PD-L1-positive TNBC. The panelists and German 
experts stated that this has no impact on early TNBC. Cur-
rently, there are no mature study data available on a PD/
PD-L1 inhibitor in early TNBC. Neither the St. Gallen 
panelists (79.2%) nor the German expert group, therefore, 
consider that routine PD-L1 determination in early TNBC 
is indicated. This also applies to PD-L1 determination on 
the immune cells (majority vote: 91.5%), which supports 
the treatment indication in the metastatic setting [5, 6]. 
Impact of Multigene Signatures
Multigene signatures may support the decision to treat 
with or without chemotherapy in patients with ER+/
HER2 early breast cancer. A majority of more than 90% 
of the St. Gallen panelists recommend the use of multi-
gene expression analyses for patients with T1/2 breast 
cancer without lymph node involvement (93.6%), and a 
majority also recommend this for patients with T3N0 
cancer (74.5%) and patients with 1‒3 positive lymph 
nodes regardless of the T stage (78.7%). 
From the German point of view, multigene expression 
analyses should only be used when the classic clinical pa-
rameters leave doubts about whether a chemotherapy is in-
dicated or not (Fig. 1) [1]. In patients with lymph node in-
volvement, the German experts consider that multigene ex-
pression analyses play no role in routine, because their 
clinical value has not been validated in prospective studies 
in these patients thus far. The German expert group also 
refers to the recommendations of the AGO Mamma, ac-
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cording to which any of the 4 available multigene signa- 
tures – Oncotype DX® Recurrence Score (RS), Mamma-
Print 70® (MP), Prosigna® PAM 50 Risk of Recurrence 
Score, and EndoPredict® – can be used in Germany (Fig. 1) 
[1].
Endocrine Adjuvant Therapy 
Endocrine adjuvant treatment is the treatment of 
choice for patients with ER+ (hormone sensitive) breast 
cancer [1]. The ideal cutoff value for the use of endocrine 
therapy is ER > 10% according to a simple majority vote 
(38.8%) of the panelists. Just under 25% of the panelists 
indicated that the cutoff is not clearly defined, and 30.1% 
saw the cutoff as ER > 1%. 
The vote illustrates that there is no ideal cutoff value. 
From the German point of view, an ER value from ≥1% 
formally constitutes an indication for endocrine therapy. 
That is why this situation should be discussed in the tu-
mor board and with the patient, taking into account oth-
er factors such as the patient’s age and additional prog-
nostic factors. 
Premenopause: When Is There an Indication of 
Ovarian Function Suppression? 
Ovarian function suppression (OFS; GnRH ana-
logues or by bilateral ovariectomy) is an additional op-
tion for endocrine therapy with tamoxifen for premeno-
pausal patients with early ER+ breast cancer. The St. 
Gallen panelists (68.1%) and the German expert group 
consider OFS to be indicated with a high risk of relapse, 
which also justifies a chemotherapy indication. They 
also agree that neither a moderate risk without chemo-
therapy indication nor a positive HER2 status (“by it-
self”) justify OFS. 
The German expert group does not agree with the fol-
lowing panelist recommendations: according to the pan-
Fig. 1. AGO recommendation 2019 on the use of multigene signa-
tures [1]. With kind permission from AGO Mamma.
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elists’ majority vote, there is an indication for OFS “by 
itself” in patients aged ≤35 years (84.8%) with a divergent 
result of multigene expression analysis (59.6%) and with 
1 previously affected lymph node (37.8%). The German 
expert group does not agree with these votes due to the 
following rationale: 
• Young age by itself is not usually a mandatory indica-
tion for OFS. 
• There are currently no data on the reliability of multi-
gene expression analyses in terms of escalating endo-
crine therapy. 
• The crucial requirement for an OFS indication is “per-
sistent ovarian function” following (neo)adjuvant che-
motherapy as well as an increased risk of relapse. This 
is the case if there are 4 positive lymph nodes; with 1‒3 
positive lymph nodes, it is dependent on further risk 
factors. 
The St. Gallen panelists (55.1%) and the German ex-
pert group agree on the duration of therapy: If indicated, 
the OFS should ideally be administered for 5 years [7]. If 
premenopausal patients receive an aromatase inhibitor 
(AI), additional OFS is mandatory. Under tamoxifen, on 
the other hand, OFS may be terminated early, if it is nec-
essary due to side effects, for example.
Endocrine Treatment Options under Discussion for 
Postmenopausal Patients
The German expert group agrees with the panelists’ 
majority vote (95.7%) that postmenopausal patients with 
ER+ early breast cancer should receive an AI at some time 
during their course of therapy. Indications for AI are G3 
cancer, a high Ki-67 value, or a positive HER2 status. The 
German expert group added that the listed factors are not 
predictive of AI administration but implicate an increased 
risk of relapse. There is no consensus that an AI should 
necessarily be given from the beginning (“upfront”). 
However, upfront administration of an AI is recom-
mended with an increased risk due to advanced tumor 
stage.
Premenopausal Patients: Therapy after 5 Years of 
Tamoxifen 
In stage I breast cancer patients who are still premeno-
pausal after 5 years of tamoxifen therapy, endocrine ther-
apy should be discontinued according to a simple major-
ity vote of the panelists (54.3%). The German expert 
group agrees but points out that case-by-case decisions 
may be possible, amongst other things, depending on the 
patient’s safety needs. 
There is a consensus that premenopausal patients with 
stage II breast cancer and lymph node involvement at first 
diagnosis are at increased risk. Therefore, they should re-
ceive tamoxifen for another 5 years (79.6%). Treatment 
should not be stopped. 
Postmenopausal Situation: Indication of Extended 
Endocrine Therapy 
Endocrine therapy beyond 5 years requires that treat-
ment has been well tolerated in the first 5 years. With this 
premise, extended endocrine therapy may be an option 
for patients with stage II ER+ breast cancer. 
The majority of panelists agree that the following situ-
ations constitute an indication for extended endocrine 
therapy:
• Stage II patients treated with tamoxifen for the first 5 
years regardless of lymph node involvement at first di-
agnosis (N0: 68.1%, N+: 97.9%). 
• Stage II patients with lymph node involvement at first 
diagnosis treated with an AI for 5 years (81.2%). 
The majority of panelists agree that there is no indica-
tion for extended endocrine therapy for these patients:
• Stage I patients, regardless of which prior endocrine 
therapy (tamoxifen or AI) has been given. 
• Stage II patients, if there was no lymph node involve-
ment at first diagnosis and if patients had an AI for 5 
years.
The German expert group agrees with the voting re-
sults. However, they point out that extended endocrine 
therapy may also be an option in patients at supposedly 
low risk (stage I or stage II [N0, AI upfront therapy for 5 
years]). The treatment decision depends on the risk-ben-
efit ratio and on patient preference after the patient has 
been thoroughly informed. 
Opinions differ about the duration of the extended 
endocrine therapy: Just under 60% of panelists voted in 
favor of extended endocrine therapy for 5 years, equiva-
lent to a total duration of therapy of 10 years. Just under 
one-third (31.7%) voted for a total duration of treatment 
of 7‒8 years. From the German perspective, duration of 
therapy depends on the endocrine pretreatment and 
should be differentiated accordingly: A total treatment 
duration of 10 years is an option for patients with 5-year 
tamoxifen pretreatment. If patients already had an AI in 
the first 5 years, extended endocrine treatment is prefer-
ably continued for 2‒3 years, equivalent to an overall du-
ration of therapy of 7‒8 years. If there is a particularly 
high risk of relapse (e.g., ≥10 positive lymph nodes, G3, 
etc.), extended endocrine therapy may even be possible 
for more than 10 years. 
Chemotherapy Indication in Patients with Low-Risk 
Cancer
According to the majority of St. Gallen panelists 
(64.6%), there is an indication for adjuvant chemother-
apy in patients with 4‒9 positive lymph nodes at first 
diagnosis. This also applies to luminal A breast cancer 
(ER+/HER2, G1 with/without low risk of relapse ac-
cording to multigene expression analysis) and to the 
“classic” lobular low-risk breast cancer (according to 
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multigene expression analysis). The German expert 
group agrees.
Multigene Signatures in Patients with No Lymph Node 
Involvement
This year, the votes on multigene signatures mainly 
related to prospective studies, such as the TAILORx [8] 
or MINDACT studies [9]. According to the TAILORx 
study [8] patients without lymph node involvement and 
an RS ≤25 do not need chemotherapy. In premenopausal 
patients (< 50 years) with an RS of 21‒25, a small majority 
(52.1%) of panelists would consider adjuvant chemother-
apy in addition to endocrine therapy with/without OFS. 
10.4% of panelists voted in favor of adjuvant OFS. About 
a quarter of the panelists voted in favor of adjuvant OFS 
but saw no indication for chemotherapy. 
The German expert group confirms that chemotherapy 
is indicated in these patients. Patients who continue to be 
premenopausal after chemotherapy should receive OFS in 
addition to endocrine therapy. If the patient is clearly post-
menopausal, then endocrine therapy without OFS should 
be given following chemotherapy. 
57.1% of panelists consider that chemotherapy in post-
menopausal patients without lymph node involvement and 
an RS ≥26 depends on the other histopathologic criteria, as 
well as on the patient’s preference. The German expert 
group agrees with this majority vote.
Multigene Expression Analyses in Patients with Lymph 
Node Involvement
The Plan B [10] and MINDACT studies [9] validated RS 
and MP also in patients with lymph node involvement. 
Taking the results of the Plan B study into account, a ma-
jority (78.7%) of the panelists consider that adjuvant che-
motherapy is not indicated in patients with an RS < 11 nor 
in patients aged > 50 years and with 1‒2 positive lymph 
nodes. From a German perspective, age-related classifica-
tion is difficult because pre- and postmenopausal patients 
were randomized in the Plan B study. German experts fail 
to agree on whether adjuvant chemotherapy is indicated in 
younger patients (< 50 years) with 1‒2 positive lymph nodes 
and low RS (RS < 11). One half voted for and the other half 
against chemotherapy. 
According to the MINDACT study [9], there is no indi-
cation for adjuvant therapy in patients at low risk (MP 
score) with 1‒2 positive lymph nodes. The panelists and the 
German expert group agree that this applies regardless of 
age, both for patients aged < 50 years (majority vote: 78.7%) 
and for those > 50 years (majority vote: 80.9%). 
Indication for Neoadjuvant Endocrine Therapy
Postmenopausal patients with a luminal A-like subtype 
that is confirmed by immunohistochemistry or multigene 
expression analysis are, in general, candidates for endo-
crine therapy. In the context of neoadjuvant treatment, 
neoadjuvant endocrine therapy should, therefore, be pre-
ferred over neoadjuvant chemotherapy. The German ex-
pert group agrees with this majority vote of the panelists 
(81.2%). Neoadjuvant therapy should continue until opti-
mal reduction of the tumor burden is achieved. This usu-
ally means a treatment duration of more than 6 months.
Adjuvant and Neoadjuvant Chemotherapy
Chemotherapy in ER+ N0 Patients
Patients with an ER+ breast cancer and no lymph node 
involvement (N0) should preferably receive chemotherapy 
containing a taxane plus an alkylating agent, if there is a 
chemotherapy indication. This majority vote (54.2%) of the 
panelists is not consistent with the AGO recommendation 
[1]. In Germany, anthracycline/taxane-based regimens 
plus an alkylating agent are preferred. In individual cases 
– for example, to avoid side effects of anthracyclines – an 
anthracycline-free regimen, such as the combination of 
docetaxel/cyclophosphamide, may be given [11].
Chemotherapy in TNBC 
In TNBC, the majority of the St. Gallen panelists pre-
ferred an anthracycline/taxane-based regimen plus an al-
kylating agent already starting from stage I (stage I: 77.6%; 
stage II or III: 93.3%). This is consistent with the AGO rec-
ommendation [1]. However, with pT1a/b TNBC, the ma-
jority of panelists (52.2%) would not use anthracyclines. 
According to the AGO recommendations, an alkylating 
agent/taxane-based regimen with/without anthracycline is 
an evidence-based option [1]. The German experts add that 
the neoadjuvant use of chemotherapy is preferable for pa-
tients with TNBC due to the verification of response that is 
possible and important for prognosis. The panelists (61.0%) 
Fig. 2. AGO recommendation 2019 for subgroup-specific sys-
temic therapy in early breast cancer [1]. With kind permission 
from AGO Mamma.
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and the German experts agree that in the (neo)adjuvant set-
ting, anthracycline/taxane-based regimens should prefer-
ably be used in a dose-dense manner (Fig. 2) [1].
Neoadjuvant Use of Platinum
The neoadjuvant use of platinum is a subject of debate 
in patients with TNBC. A higher rate of pathologic com-
plete response (pCR) is achieved with platinum-based neo-
adjuvant chemotherapy [12–15]. In the GeparSixto study, 
the higher pCR rate for the entire cohort of TNBC pa- 
tients – irrespective of BRCA1/2 status – translated into a 
longer disease-free survival (DFS; p < 0.001) [14]. The AGO 
Mamma recommends the neoadjuvant use of platinum for 
high-risk patients (high tumor burden, poor response) 
(Fig. 2). The German expert group, therefore, does not agree 
with the majority vote of the St. Gallen panelists (56.5%), who 
see no neoadjuvant indication for platinum in addition to an 
anthracycline/alkylating agent/taxane-based regimen. 
Moreover, the German expert group does not agree 
with the majority vote of the panelists (67.3%) to limit the 
neoadjuvant use of platinum to patients with BRCA mu-
tation. The BRCA mutation itself is not a predictor of the 
use of platinum. It increases tumor chemotherapy sensi-
tivity but not specifically the sensitivity to platinum [14]. 
Chemotherapy for Patients with Small TNBC 
(pT1apN0)
Even in a patient with a small, unifocal TNBC without 
lymph node involvement (< 6 mm, N0), chemotherapy 
may be indicated according to the majority (65.3%) of the 
panelists. From the German point of view, this is a case-
by-case decision. German experts see a chemotherapy in-
dication in this situation primarily for young patients 
with highly proliferative tumors or in patients with a high 
desire for safety (patient preference).
Votes on HER2-Positive Breast Cancer
There is a high level of agreement between the votes of 
the panelists and of the German expert group concerning 
anti-HER2-directed treatment for HER2-positive 
(HER2+) early breast cancer patients: 
• Patients with HER2+ breast cancer receive anti-HER2 
therapy in addition to chemotherapy. This applies 
from stage I [1] but is not the standard for T1a breast 
cancers with no lymph node involvement (N0) (ma-
jority vote: 55.3%). 
• For patients with stage I disease, the adjuvant use of 
trastuzumab with chemotherapy is the standard of 
care regardless of ER status (majority vote: 61.7%). 
The preferred adjuvant regimen is the combination of 
taxane/trastuzumab in this situation (majority vote: 
73.5%). 
• If there is a neoadjuvant indication for trastuzumab in 
patients with HER2+/ER+ stage I breast cancer, this 
does not imply that an adjuvant application of pertu-
zumab is the standard of care (majority vote: 52.1%; 
14.6% abstained).
• Pertuzumab is approved at stage I in patients with 
lymph node involvement (N+) and/or negative ER sta-
tus and is also recommended as such by the AGO 
Mamma [1]. In contrast, the St. Gallen panelists (ma-
jority vote: 48.9%) do not consider dual antibody 
blockade with pertuzumab to be indicated in stage I 
HER2+ breast cancer. This is not in line with the AGO 
recommendations [1].
• Patients at stage II with lymph node involvement (N+) 
or those at stage III should preferably receive (neo)
adjuvant combination therapy with doxorubicin/cy-
clophosphamide (AC) or epirubicin/cyclophospha-
mide followed by a taxane plus dual antibody block-
ade (trastuzumab/pertuzumab) (majority vote: 
75.5%). 
• Dual antibody blockade with trastuzumab/pertuzu-
mab is the preferred treatment option for all patients 
at stage II (N+) or stage III (majority vote: 76.6%).
• If trastuzumab is indicated, duration of therapy is 12 
months (majority vote: 89.8%). 
Indication for Neratinib
In HER2+ early breast cancer patients, the adjuvant 
application of neratinib is an option following (neo)adju-
vant trastuzumab. However, in the registration study Ex-
teNET [16], a very selective group of patients benefited 
from neratinib – those with HER2+/ER+ breast cancer 
and at least 4 positive lymph nodes. Due to significant 
toxicity, the adjuvant use of neratinib is seen with caution. 
Only 21% of the St. Gallen panelists voted in favor of ne-
ratinib for all patients with HR+/HER2+ breast cancer 
and lymph node involvement, 27% voted in favor of ne-
ratinib in patients with at least 4 positive lymph nodes, 
and 29.2% abstained. 
The German expert group also refers to the substantial 
toxicity (diarrhea). Based on the ExteNET study, the AGO 
Mamma recommends neratinib as a plus/minus (+/–) de-
cision [16], which translates to a case-by-case option [1]. 
There is no indication for adjuvant neratinib use after dual 
antibody blockade, as data are lacking.
Tumor Residue after Neoadjuvant Systemic Therapy
The St. Gallen panelists and the German expert group 
agree that neoadjuvant systemic therapy is the preferred 
treatment concept for patients with stage II/III TNBC or 
HER2+ breast cancer. This applies regardless of whether 
breast-conserving surgery is feasible or not (majority vote: 
98.0%). The key benefit of the neoadjuvant concept is the 
verification of response [1]. 
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If a residual tumor remains in TNBC after neoadjuvant 
sequential therapy with AC-taxane, these patients should 
receive further adjuvant capecitabine [17, 18]. This rec-
ommendation applies regardless of the size of the residual 
tumor (≥/< 1 cm) and lymph node involvement (N+/N0). 
The German experts agree with the majority vote of the St. 
Gallen panelists.
Post-neoadjuvant T-DM1 is a new option for patients 
with HER2+ breast cancer and residual tumor in the breast 
and/or axilla after neoadjuvant systemic therapy [19]. 
More than 90% of St. Gallen panelists as well as the Ger-
man expert group agree. Neither the size of the residual 
tumor nor the tumor burden in the axilla is of any impor-
tance for the indication of T-DM1. It is also negligible 
whether patients had received trastuzumab or dual anti-
body blockade with trastuzumab/pertuzumab in addition 
to neoadjuvant chemotherapy. 
pCR after Neoadjuvant Systemic Therapy
A point of debate is the adjuvant treatment of patients 
with HER2+ breast cancer and pCR after neoadjuvant 
therapy. When patients with lymph node involvement at 
first diagnosis achieve pCR under neoadjuvant polyche-
motherapy and dual antibody blockade (trastuzumab/
pertuzumab), a simple majority (47.7%) of the St. Gallen 
panelists prefers to continue adjuvant treatment with 
both antibodies; 38.6% would only use adjuvant trastu-
zumab. The German expert group agrees with the major-
ity vote, although this is not yet evidence based. As a ra-
tionale, the German experts refer to the tumor biology, 
which would not be changed after pCR. That is why the 
increased risk still exists and justifies dual antibody 
blockade. 
From a German perspective, this is also true for pa-
tients without lymph node involvement (cN0) at first di-
agnosis, when both antibodies were used in addition to 
neoadjuvant polychemotherapy (according to approval in 
HER2+/ER). In this case, the majority of St. Gallen panel-
ists (52.2%) voted in favor of the adjuvant treatment with 
trastuzumab alone. From a German perspective, de-esca-
lation is not indicated if there is an increased baseline risk 
(e.g., ER–). 
Adjuvant Bone-Modifying Therapy
Adjuvant use of a bisphosphonate (zoledronic acid ev-
ery 6 months or daily oral clodronate) in addition to adju-
vant endocrine therapy can prolong DFS in postmeno-
pausal patients and improve overall survival. This ap- 
plies regardless of the bone density [20]. The Austrian 
ABCSG-12 study [21] shows that the improvement of out-
come due to adjuvant bisphosphonates can also be seen in 
premenopausal patients if they receive concomitant ovar-
ian suppression (GnRH analogue) as part of an adjuvant 
endocrine therapy. 
In the context of these data, a small majority (53.1%) of 
the panelists supported the concomitant administration 
of a bisphosphonate (zoledronic acid or clodronate) in 
premenopausal patients who received an adjuvant GnRH 
analogue plus tamoxifen or AI. The rationale is to prolong 
DFS regardless of bone density. 
The German expert group does not agree on this ques-
tion. It was debated that the indication in favor of a 
bisphosphonate for DFS prolongation in premenopausal 
patients is based on only 1 study (ABCSG-12) [21]. The 
AGO Mamma has thus given a plus/minus rating (case-
by-case decision) [1]. The German experts do agree that 
the osteoprotective effect of bisphosphonates is not 
linked to the adjuvant indication regarding DFS prolon-
gation. 
In postmenopausal patients, the German experts agree 
with the St. Gallen panelists (83.7%) that bisphospho-
nates can be used for DFS prolongation. Interestingly, 
however, only 42.6% of the panelists confirmed, in an ad-
ditional vote, that they implement this in their own clini-
cal practice. 
With respect to controversial study data, there is no in-
dication for adjuvant denosumab (60 mg, every 6 months) 
to prolong DFS. Concerning this point, the German experts 
agree with the majority vote (75%) of the St. Gallen panel-
ists. Unlike the ABCSG-18 study [22, 23], the registration 
study of denosumab (D-CARE) [23] did not confirm an 
improved chance for cure with denosumab. However, the 
D-CARE study also saw a positive impact on the fracture 
rate [24]. 
Fig. 3. AGO recommendation 2019 on fertility protection under 
(neo)adjuvant chemotherapy [1]. With kind permission from 
AGO Mamma.
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Fertility Preservation Should be Offered
Fertility preservation by suppression of ovarian func-
tion should be offered to all patients under (neo)adjuvant 
chemotherapy who want to have children [1], regardless of 
the tumor’s HR status. The German expert group agrees 
with the majority vote of the panelists both for patients with 
HR-negative (91.5%) and HR-positive breast cancer 
(79.6%). This should apply to all patients at childbearing 
age. The German experts refer to the AGO recommenda-
tions for more information (Fig. 3) and to the FertiPRO-
TEKT initiative (www.fertiprotekt.de).
Genetic Testing for High-Risk Mutations
Genetic testing for high-risk mutations (e.g., BRCA1/2 
testing) requires appropriate education and advice for the 
patient. The German expert group agrees with the major-
ity vote (70.8%) of the St. Gallen panelists that such testing 
should not be considered for all patients, regardless of the 
familial risk. The panelists’ vote whether genetic testing 
should be recommended to women from high-risk fami-
lies (clearly positive family history) was unanimous 
(100%!). The panelists’ vote whether genetic testing should 
be performed in patients under the age of 35 years at the 
time of first diagnosis was almost unanimous (95.9%). 
There is consensus that a cutoff by age below 50 years is 
not suitable to recommend genetic testing without a family 
history. There is, therefore, no general indication for testing 
patients younger than 50 years. This is different for patients 
with TNBC. In this case, the St. Gallen panelists (85.4%) 
and the German experts recommend genetic testing if the 
patient is younger than 60 years at initial diagnosis. 
Pregnancy after Breast Cancer
Breast cancer patients who want to have children 
should be actively counseled. Endocrine treatment may 
be interrupted to have a child, if there is no high-risk sit-
uation. This should be performed earliest after 18 months 
(78.0%). The German expert group, therefore, agrees 
with the majority vote (79.2%) of the panelists that ther-
apy should not be discontinued at any time. Since the 
benefit of adjuvant endocrine therapy correlates with du-
ration of therapy, the German experts favor a therapy du-
ration of at least 24 months before pregnancy occurs. 
Almost 60% of the St. Gallen panelists recommend that 
the patient should undergo re-staging prior to pregnancy. 
The German expert group also recommends re-staging. 
Regardless of this, the desire to have children is an indi-
vidual patient decision. The treating physician should ed-
ucate the patient and constructively support her.
Ductal Carcinoma in situ
The voting questions posed during the St. Gallen Con-
sensus Meeting for treatment of ductal carcinoma in situ 
(DCIS) do not adequately reflect the complexity of the 
situation. In this context, the German expert group agrees 
with the St. Gallen panelists (97.9%) that patients with a 
small DCIS have a more favorable prognosis and need less 
intensive treatment. This applies especially if the DCIS is 
detected during screening, the patient is ≥50 years of age, 
and the DCIS has a favorable low-risk biology. 
Favorable prognostic factors and a free margin (≥5 
mm) may support the omission of adjuvant radiothera-
py of the DCIS according to the panelists’ vote (84.4%). 
The question whether to omit adjuvant endocrine treat-
ment was supported by a small majority (55.6%) of pan-
elists for all DCIS patients and by 42.2% for DCIS pa-
tients with favorable prognostic factors. In patients with 
favorable prognostic factors, 66.7% of panelists would 
omit both adjuvant radiotherapy and adjuvant endo-
crine therapy.
The German expert group points to the fact that the 
use of tamoxifen is primarily a preventive intervention to 
prevent ipsilateral or contralateral secondary breast can-
cer. The decision to administer adjuvant treatment to a 
patient with DCIS requires an individual risk-benefit as-
sessment which is guided by various factors, such as tu-
mor size or patient age. No survival benefit has been re-
ported to date for DCIS patients, neither for endocrine 
therapy nor radiation therapy. The safety margin of ≥5 
mm in the voting questions is arbitrary in the view of the 
German experts, because no definitive margin is current-
ly defined for DCIS.
Magnitude of Absolute Benefit
More than 90% of the panelists voted that breast can-
cer patients should also be informed of the possibilities 
and limitations of a therapeutic intervention. Treatment 
options with only a very limited chance to be successful 
should be communicated honestly; the option to avoid 
this treatment should also be discussed with the patient. 
The German expert group agrees without reservations.
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